These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34967815)

  • 1. Triple negative breast cancer: any closer to cracking the code?
    Peddi PF
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    Sakach E; O'Regan R; Meisel J; Li X
    Clin Breast Cancer; 2021 Dec; 21(6):509-520. PubMed ID: 34629314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
    Davis AA; Gradishar WJ
    Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies for the management of triple-negative breast cancer.
    Riaz F
    Curr Opin Obstet Gynecol; 2024 Feb; 36(1):40-44. PubMed ID: 38170551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatment of Triple-Negative Breast Cancer.
    Young JA; Tan AR
    Cancer J; 2021 Jan-Feb 01; 27(1):50-58. PubMed ID: 33475293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates in triple negative breast cancer.
    Tray N; Adams S; Esteva FJ
    Future Oncol; 2018 Oct; 14(25):2651-2661. PubMed ID: 30175620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Therapeutic Strategies for Triple-Negative Breast Cancer.
    Székely B; Silber AL; Pusztai L
    Oncology (Williston Park); 2017 Feb; 31(2):130-7. PubMed ID: 28205193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
    Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
    Abahssain H; Souadka A; Alem R; Santoni M; Battelli N; Amela E; Lemaire A; Rodriguez J; Errihani H
    Curr Oncol; 2024 Jun; 31(7):3771-3782. PubMed ID: 39057150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancer: recent treatment advances.
    Bergin ART; Loi S
    F1000Res; 2019; 8():. PubMed ID: 31448088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.